<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02496910</url>
  </required_header>
  <id_info>
    <org_study_id>YH22162-102</org_study_id>
    <nct_id>NCT02496910</nct_id>
  </id_info>
  <brief_title>PK Study of YH22162 FDC Compared to Combination of Twynsta and Hygroton</brief_title>
  <official_title>A Randomized,Open-label,Single Dose,Crossover Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Comparison to the Co-administration of Twynsta and Hygroton in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Randomized, open-label, single-dose, 2-treatment, 2-period, 2-sequence crossover
      design.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 2 by 2 cross-over study to evaluate pharmacokinetics of YH22162 FDC compared to
      reference twynsta and Hygroton co-administered in two groups enrolling healthy adult male
      subjects under fasting conditions.

      Subjects will be admitted to the clinic in the evening before Day 1. All subjects will
      receive a single oral dose of YH22162 FDC or twynsta and Hygroton co-administered in the
      morning on Day 1. All the subjects will remain in the clinical unit until completion of all
      assessments on Day 2 including collection post-dose PK sample. Subjects will return to the
      clinic for pharmacokinetic samples at scheduled time. The two treatment periods will be
      separated by a washout period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence study is based on Cmax and AUC parameters</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Group 1 - Period 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmisartan/Amlodipine 80/5 mg (FDC) and Chlorthalidone 25mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YH22162 FDC tablet of Yuhan Corporation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1 - Period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YH22162 FDC tablet of Yuhan Corporation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Period 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmisartan/Amlodipine 80/5 mg (FDC) and Chlorthalidone 25mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH22162</intervention_name>
    <arm_group_label>Group 2 - Period 1</arm_group_label>
    <arm_group_label>Group 1 - Period 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan/Amlodipine 80/5 mg (FDC)</intervention_name>
    <arm_group_label>Group 1 - Period 1</arm_group_label>
    <arm_group_label>Group 2 - Period 2</arm_group_label>
    <other_name>Twinstar 80/5 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorthalidone 25mg</intervention_name>
    <arm_group_label>Group 1 - Period 1</arm_group_label>
    <arm_group_label>Group 2 - Period 2</arm_group_label>
    <other_name>Hygroton 25mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male and female with a body mass index(BMI) between 18.5 and 25 kg/m2

          2. Who has not suffered from clinically significant disease

          3. Provision of signed written informed consent

        Exclusion Criteria:

          1. History of and clinically significant disease

          2. A history of drug abuse or the presence of positive reactions to drugs that have abuse
             potential in urine screenings for drugs.

          3. Administration of other investigational products within 3 months prior to the first
             dosing.

          4. Volunteers considered not eligible for the clinical trial by the investigator (study
             doctor) due to reasons including laboratory test results, ECGs, or vital signs.

          5. Sitting blood pressure meeting the following criteria at screening: 150 ≥ systolic
             blood pressure ≤100 (mmHg) and 100 ≥ diastolic blood pressure ≤ 60 (mmHg)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mingul Kim, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Chunju</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2015</study_first_submitted>
  <study_first_submitted_qc>July 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2015</study_first_posted>
  <last_update_submitted>September 24, 2015</last_update_submitted>
  <last_update_submitted_qc>September 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Chlorthalidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

